Scientists from the University of California have announced a possible alternative option to electronic eye implants for those who have lost their sight: gene therapy. Virus-delivered genes for green opsin gave blind mice sight enough to determine patterns on an iPad, they found, with the therapy possibly ready for clinical trials in three years’ time.
Disruptive science can have a significant impact outside of our own domains of research and into our personal lives. Keeping abreast of these developments can help prepare and inspire.
The scientists of seven nations have called for a halt to gene-editing experiments seeking to alter heritable traits in human babies.
Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
A second individual has experienced sustained remission from HIV after their treatment ended, scientists from the University of Central London and Imperial College have found.
Biogen has announced it will acquire Nightstar Therapeutics for around $800m, providing the pharma giant with a pipeline of gene therapy candidates for ophthalmology.
Twins born in Australia have become the second-ever-identified pair of “semi-identical” twins, and the first to be detected before they were born. Such cases come about when twins receive 100% identical genes from their mother, but not from their father.
New information from China has suggested that the twins recently created using CRISPR gene-editing technology to make them HIV-resistance could also develop genetically-enhanced brains.
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Scientists have used synthetic nucleotides to double the traditional number of life’s building blocks to eight.
Roche is set to pay $4.3bn for the acquisition of Spark Therapeutics, a gene therapy company that will put the pharma giant ahead in one of the biggest growing markets around.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.